Related Experiment Video
Updated: Mar 3, 2026
09:02
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
5.0K
Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of
Yu-Cheng Chiang1, Dao-Fu Dai2, Yi-Wen Chiu3
1Department of Medical Education, Cathay General Hospital, Taiwan.
Kidney Medicine
|March 2, 2026
Summary
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) significantly reduce acute kidney injury risk, offering renoprotective benefits. However, they are linked to increased risks of infections and diabetic ketoacidosis, necessitating careful patient monitoring.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 inhibitors (SGLT2is) demonstrate cardiovascular and renal protective effects.
- Their safety profile, particularly regarding acute kidney injury (AKI) and other adverse events (AEs), requires comprehensive evaluation across diverse patient groups.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating the risks of AKI and other AEs associated with SGLT2is.
- To assess the efficacy and safety of SGLT2is in various populations, including those with and without type 2 diabetes and chronic kidney disease (CKD).
Main Methods:
- A systematic review and meta-analysis of 13 RCTs involving 84,581 participants, published up to December 31, 2023.
- Data extraction by two independent reviewers, focusing on renal and nonrenal AEs.
- Random-effects meta-analysis to calculate pooled relative risks and odds ratios with 95% confidence intervals (CIs).
Main Results:
- SGLT2is were associated with a 20% reduction in AKI risk (RR, 0.80; 95% CI, 0.74-0.87) with low heterogeneity.
- In patients with CKD, SGLT2is significantly reduced renal composite outcomes (OR, 0.70; 95% CI, 0.62-0.79).
- Increased risks were observed for genital infections, urinary tract infections, diabetic ketoacidosis, and hypovolemia, while no significant differences were found for hypoglycemia or lower limb amputation.
Conclusions:
- SGLT2is provide significant renoprotective benefits, reducing AKI and renal composite outcomes.
- The benefits must be weighed against increased risks of specific nonrenal AEs, including infections and diabetic ketoacidosis.
- Tailored treatment strategies and close monitoring are essential for optimizing SGLT2i safety and efficacy, particularly in high-risk individuals.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
397
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
397
01:29Acute Kidney Injury II: Pathophysiology
1.4K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.4K
01:22Acute Kidney Injury I: Introduction
946
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
946
01:20Acute Kidney Injury V: Interprofessional Care
416
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
416
01:29Acute Kidney Injury III: Clinical Manifestations
1.1K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.1K
01:22Acute Kidney Injury VI: Nursing Management
589
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
589